Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company, has announced a clinical collaboration with Merck subsidiary, MSD, a global, clinical-stage biotechnology company, it was reported on Monday.
The collaboration is aimed at assessing the combination of Ascentage Pharma's MDM2-p53 inhibitor, APG-115, and Merck's KEYTRUDA (pembrolizumab) intended for the treatment of patients with advanced solid tumours.
Under the agreement, Ascentage is to support an open-label, multicentre, phase Ib/II study (NCT03611868) intended to assess the safety and efficacy of both the products in multiple cohorts of solid tumours. The Phase II part of the study has commenced and is likely to enrol 80 patients at multiple sites in the United States. Both parties are to use a joint development committee to exchange information about the study.
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
GSK commits USD30bn to US R&D and manufacturing expansion
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial